Events & Presentations

Recent Events

  • NIH Fast Track STTR Phase I/II award, R42 HL145930 “Novel Therapeutic Antibody Targeting of Extracellular NAMPT in Ventilator-Induced Lung Injury” will be funded beginning in December 2018
  • Hiring of Stan G. Miele as the Chief Business/Strategy Officer. Mr Miele has extensive biotech sales and marketing knowledge, P&L Leadership in pharmaceutical and medical device industries and a proven sales acceleration record.
  • Successful submission of a trademark application to the U.S. Patent and Trademark Office for eNamptor™, our human monoclonal antibody.
  • Established preliminary agreement with Fusion Antibodies to develop both a transient and stable cell line monoclonal antibody IgG version of eNamptorTM for both acute and chronic lung indications.
  • Submission of a $3 million Department of Defense Therapeutic Development Award “eNamptorTM as a Novel Therapy for Trauma-Induced Acute Lung Injury” targeting ‘at risk’ military casualties.
  • Submission of a $3 million Department of Defense Impact Award “Targeting NAMPT to attenuate progression to lethal prostate cancer” focused on reducing inflammation and transition to an aggressive cancer.
  • Submission of a Phase I STTR entitled “ The CRIT-ICU Biomarker Panel for Stratification of Mortality Risk in ARDS Patients”. This application is based on our ongoing work to identify a novel panel of ICU biomarkers that predict mortality and represents another piece of important intellectual property for Aqualung Therapeutics Corporation investors.
  • Filing of U.S. Patent PCT “Methods for Treating Pulmonary Hypertension” in April 2018.Licensed exclusively to Aqualung Therapeutics.
  • Filing of U.S. Patent PCT “Methods for Treating Pulmonary Fibrosis” in April 2018.Licensed exclusively to Aqualung Therapeutics.
  • Two(2) Human monocolonal anti-NAMPT antibodies identified and studied in ex vivo assays.

Upcoming Events:

No upcoming events

Past Events:

NIH Phase I STTR awarded, eNamptorTM 2013

Two Human monoclonam anti-NAMPT Fabs identified

NAMPT is a therapeutic target in Pulmonary Arterial Hypertension – key manuscript published.

Nicotinamide phosphoribosyl transferase promotes pulmonary vascular remodeling and is a therapeutic target in Pulmonary Arterial Hypertension Circulation.

135(16): 1532 – 1246 PMID 282024896, 2017

NAMPT is a therapeutic target in Pulmonary Fibrisis. VA Merit Review: The role of NAMPT in age associated persistent lung fibrosis.